Has Georgette Dakis received payments from drug or device companies?

Yes. Drug and device makers reported $2,234 in general payments to Georgette Dakis across 114 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Georgette Dakis did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Georgette Dakis come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Georgette Dakis

Family · Burlingame, CANPI 1801063912

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations.

$2,234in general payments, 2019–2025

Across 114 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Mayne Pharma Commercial LLC$522
AbbVie$248
Exact Sciences$166
Biohaven Pharmaceutical Holding Company Ltd.$165
Biogen$143
Astellas Pharma US Inc$134
plus $856 from 17 others

What the payments were for

Food & beverage$2,234100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Mayne Pharma Commercial LLC	34	$522
AbbVie	12	$248
Exact Sciences	7	$166
Biohaven Pharmaceutical Holding Company Ltd.	7	$165
Biogen	8	$143
Astellas Pharma US Inc	5	$134
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	6	$119
Myovant Sciences Inc.	5	$101
Pfizer	5	$94
Takeda Pharmaceuticals U.S.A., Inc.	4	$79
Therapeuticsmd, Inc.	4	$75
Biohaven Pharmaceuticals, Inc.	2	$55
Hologic Sales And Service, LLC	2	$49
Sage Therapeutics, LLC	2	$48
Davol Inc.	1	$41
Sumitomo Pharma America, Inc.	2	$39
Bausch Health US, LLC	1	$31
Medicem Inc.	1	$30
Avion Pharmaceuticals	2	$23
Aspira Women's Health Inc	1	$21
Coopersurgical, Inc.	1	$19
Organon	1	$18
Agile Therapeutics, Inc.	1	$14

How this compares

$2,234 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Estradiol	21	$1,513
Cefdinir	14	$387
Levothyroxine Sodium	11	$304
Atorvastatin Calcium	16	$176
Hydrochlorothiazide	30	$143
ValacyclovirValacyclovir Hcl	12	$114
Simvastatin	17	$87

Paid to pharmacies, not to this prescriber.

Other family in Burlingame

Michelle JonesBurlingame$147K
Lori RobertsonChino Hills$475K
Annette ShonLos Angeles$406K
Lisa HigginsHanford$311K
Jennifer TougasBakersfield$302K
Kim SchaferSacramento$288K
Dawn MeyerSan Diego$270K
Jennifer KangCerritos$255K
Erin DwyerSan Diego$189K
Phyllis CasonLos Angeles$187K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →